Martin A. Lehr Purchases 100,000 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) Stock

Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin A. Lehr purchased 100,000 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were bought at an average price of $0.70 per share, with a total value of $70,000.00. Following the purchase, the chief executive officer now owns 920,190 shares in the company, valued at $644,133. The trade was a 12.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Context Therapeutics Trading Down 7.2%

Context Therapeutics stock opened at $0.62 on Thursday. Context Therapeutics Inc. has a 1-year low of $0.49 and a 1-year high of $2.75. The firm has a market capitalization of $55.64 million, a price-to-earnings ratio of -0.68 and a beta of 1.86. The firm has a 50 day simple moving average of $0.75 and a 200 day simple moving average of $0.91.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). On average, equities research analysts forecast that Context Therapeutics Inc. will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Shay Capital LLC bought a new position in shares of Context Therapeutics during the fourth quarter valued at about $52,000. MPM Bioimpact LLC purchased a new position in shares of Context Therapeutics during the fourth quarter valued at about $15,441,000. Millennium Management LLC increased its position in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after buying an additional 34,835 shares during the period. Citadel Advisors LLC purchased a new position in shares of Context Therapeutics during the fourth quarter valued at about $31,000. Finally, Allostery Investments LP purchased a new position in shares of Context Therapeutics during the fourth quarter valued at about $998,000. 14.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CNTX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Context Therapeutics currently has an average rating of “Buy” and a consensus target price of $6.00.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.